<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647086</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1433</org_study_id>
    <nct_id>NCT02647086</nct_id>
  </id_info>
  <brief_title>Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)</brief_title>
  <official_title>An Open-Label, Drug-Drug Interaction Study to Examine the Effects of Dupilumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-sequence DDI study designed to examine the effects of dupilumab&#xD;
      on the pharmacokinetics of selected cytochrome P450 substrates in adult patients with&#xD;
      moderate to severe AD.&#xD;
&#xD;
      The study consists of a screening period (day -35 to -2), study period 1 (day -1 to 7), study&#xD;
      period 2 (day 8 to 50), and a follow-up period (day 51 to 135 [end of study]).&#xD;
&#xD;
      Following completion of study period 2 (Day 50), patients will be given the option to enroll&#xD;
      into the Open-Label Extension (OLE) study R668-AD-1225. Patients who decline will be followed&#xD;
      for the next 12 weeks (Day 135).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of Area Under Curve last (AUClast) and maximum concentration (Cmax) for Cytochrome P450 substrates from pre-dupilumab administration at baseline (period 1, day 1)</measure>
    <time_frame>At Baseline (day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of AUClast and Cmax for CYP substrates 4 weeks after initiating a weekly regimen of dupilumab (period 2, day 36)</measure>
    <time_frame>At day 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) from day of first administration of dupilumab to end of study (day 50 for patients who enroll in the OLE study; day 134 for patients who decline participation in the OLE).</measure>
    <time_frame>Baseline up to day 134</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <arm_group_label>Period 2</arm_group_label>
    <other_name>REGN668/SAR231893</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Cytochrome P450 substrate</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Cytochrome P450 substrate</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Cytochrome P450 substrate</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Cytochrome P450 substrate</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Cytochrome P450 substrate</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient, aged 18 years or older&#xD;
&#xD;
          2. Diagnosis of Chronic AD, defined as diagnosis of AD for at least 3 years before the&#xD;
             screening visit&#xD;
&#xD;
          3. Eczema Area Severity Index (EASI) score ≥16 at the screening and baseline visits&#xD;
&#xD;
          4. Investigator's Global Assessment (IGA) score ≥3 (on the 0 to 4 IGA scale) at the&#xD;
             screening and baseline visits&#xD;
&#xD;
          5. ≥10% Body Surface Area (BSA) of AD involvement at the screening and baseline visits&#xD;
&#xD;
          6. Patients with documented recent history (within 6 months before the screening visit)&#xD;
             of inadequate response to outpatient treatment with topical medications, or for whom&#xD;
             topical treatments are otherwise medically inadvisable (eg, because of important side&#xD;
             effects or safety risks)&#xD;
&#xD;
          7. Provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior participation in a dupilumab clinical trial&#xD;
&#xD;
          2. The use of any of the following treatments within 4 weeks before the baseline visit:&#xD;
&#xD;
               -  Systemic corticosteroids&#xD;
&#xD;
               -  Immunosuppressive/immunomodulating drugs&#xD;
&#xD;
               -  Phototherapy for AD&#xD;
&#xD;
          3. Administration, within 14 days before baseline or within a period of 5 times the&#xD;
             elimination half-life of the medication before baseline, whichever is longer, of any&#xD;
             medication that is a known inducer or inhibitor of either one or more of the following&#xD;
             CYP enzymes: CYP3A, CYP2C19, CYP2C9, CYD2D6, and CYP1A2. Patients who are on any of&#xD;
             these medications at the time of screening and cannot be safely taken off these&#xD;
             medications will be excluded from the study.&#xD;
&#xD;
          4. Any contraindication to one or more of the following drugs, according to the&#xD;
             applicable labeling:&#xD;
&#xD;
               -  Midazolam&#xD;
&#xD;
               -  Omeprazole&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
               -  Caffeine&#xD;
&#xD;
               -  Metoprolol&#xD;
&#xD;
          5. Consumption of any 1 or more of the following food items and/ or beverages within 1&#xD;
             week prior to baseline:&#xD;
&#xD;
               -  Grapefruit or grapefruit juice, apple or apple juice, orange or orange juice,&#xD;
                  lemons or lemon juice, limes or lime juice&#xD;
&#xD;
               -  Vegetables from the mustard green family (eg, broccoli)&#xD;
&#xD;
               -  Charbroiled meats&#xD;
&#xD;
               -  Caffeinated beverages, foods or drugs containing caffeine Patients who are not&#xD;
                  willing to abstain from the consumption of these food items and/or beverages for&#xD;
                  certain periods during the study will also be excluded&#xD;
&#xD;
          6. History of excessive consumption of beverages containing caffeine (more than 4 cups or&#xD;
             glasses per day). Patients who are not willing to abstain from the consumption of&#xD;
             caffeine during certain periods of the study will also be excluded&#xD;
&#xD;
          7. History or presence of alcohol or drug abuse within last 2 years&#xD;
&#xD;
          8. History of smoking within last 2 years&#xD;
&#xD;
          9. Poor metabolizers for CYP2C9, CYP2C19, or CYP2D6 based on genotyping&#xD;
&#xD;
         10. Presence of any one or more of the following lab abnormalities at screening:&#xD;
&#xD;
               -  Platelet count ≤100 x 10^3/µL&#xD;
&#xD;
               -  Neutrophils ≤1 x 10^3/µL&#xD;
&#xD;
               -  Creatinine phosphokinase (CPK) &gt;10 x upper limit of normal (ULN)&#xD;
&#xD;
               -  International normalized ratio (INR) ≥2&#xD;
&#xD;
         11. Active chronic or acute infection requiring treatment with systemic antibiotics,&#xD;
             antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit,&#xD;
             or superficial skin infections within 1 week before the screening visit&#xD;
&#xD;
         12. Known or suspected immunodeficiency, including history of invasive opportunistic&#xD;
             infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis,&#xD;
             pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent&#xD;
             infections of abnormal frequency or prolonged duration suggesting an immune&#xD;
             compromised status, as judged by the investigator&#xD;
&#xD;
         13. History of human immunodeficiency virus (HIV) infection or positive HIV serology at&#xD;
             screening&#xD;
&#xD;
         14. Positive with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb),&#xD;
             or hepatitis C antibody (Hep C Ab) at the screening visit. NOTE: Patients who are&#xD;
             HBsAg negative and HBsAb positive are considered immune after a natural infection has&#xD;
             cleared or they have been vaccinated against hepatitis B. Therefore, they are&#xD;
             acceptable for the study.&#xD;
&#xD;
         15. History of malignancy within 5 years before the baseline visit, except completely&#xD;
             treated in situ carcinoma of the cervix, and completely treated and resolved&#xD;
             non-metastatic squamous or basal cell carcinoma of the skin&#xD;
&#xD;
         16. History of clinical endoparasitosis (ie, helminth infection) within 12 months before&#xD;
             the baseline visit, or high risk of helminth infection, such as residence within or&#xD;
             recent travel (within 12 months before the baseline visit) to areas endemic for&#xD;
             endoparasitoses, where the circumstances are consistent with parasite exposure (eg,&#xD;
             extended stay, rural or slum areas, lack of running water, consumption of uncooked,&#xD;
             undercooked, or otherwise potentially contaminated food, close contact with carriers&#xD;
             and vectors, etc), unless subsequent medical assessments (eg, stool exam, blood tests,&#xD;
             etc) have ruled out the possibility of parasite infection/infestation&#xD;
&#xD;
         17. Female patients who are pregnant, breastfeeding, or planning to become pregnant or&#xD;
             breastfeed during the study&#xD;
&#xD;
         18. Women who are using any form of hormonal contraceptives (eg, oral, injectables,&#xD;
             implants, patches, rings, hormone-impregnated intrauterine devices [IUDs]) for birth&#xD;
             control&#xD;
&#xD;
         19. Women unwilling to use adequate birth control, if of reproductive potential and&#xD;
             sexually active.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

